arrow
J

Janneke E. Stalenhoef

olvg hospital
H指数:18
被引数:1,779

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular signatures and causal factors underlying latent cytomegalovirus infection among people living with HIV (PLHIV)

潜伏巨细胞病毒感染在人类免疫缺陷病毒感染者中存在的分子特征及其病因学因素

2026-03-250
OAAI
Residual HIV viremia strongly increases cardiovascular disease incidence independent of classical risk factors

残余HIV病毒载量显著增加心血管疾病发病率,且与经典危险因素无关

2026-03-200
OAAI
Opposite effects of chronic HIV infection and antiretroviral medication on organismal and organ-specific biological aging

慢性HIV感染和抗逆转录病毒药物对机体和器官特异性生物衰老的相反影响

2026-02-100
OAAI
Circulating immune landscape and immune signatures in spontaneous HIV controllers

循环免疫景观和免疫特征在自发HIV控制者中的表现

2025-10-040
OAAI
Phenotypic and epigenetic profiles of circulating NK cells in spontaneous HIV-1 controllers

循环NK细胞在自发性HIV-1控制者的表型和表观遗传特征

2025-09-290
OAAI
Distinct metabolic perturbations link liver steatosis and incident CVD in lean but not obese PWH
2025-02-110
OAAI
HIV immunological non-responders are characterized by extensive immunosenescence and impaired lymphocyte cytokine production capacity
2024-05-081
OAAI
Liver Steatosis is Prevalent in Lean People With HIV and Associated With Exposure to Antiretroviral Treatment-A Cross-sectional Study
2024-05-075
OAAI
Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies
2024-04-101
OAAI
Diagnostic accuracy of urine biomarkers for urinary tract infection in older women: a case-control study
2024-02-016
OA
The 2000HIV study: Design, multi-omics methods and participant characteristics

2000年hiv研究: 设计,多组学方法和参与者特征

2022-12-2013
OAAI
Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
2021-11-250
PRE
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial
2021-09-01168
OAAI
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
2021-05-27122
OAAI